Virtu Financial’s Xenetic Biosciences XBIO Stock Holding History

Virtu Financial’s Portfolio XBIO Stock Details XBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,973	Closed	-$11K	–	2202
2022 Q3	$11K	Buy	+1,973	New	+$15.6K	﹤0.01%	1510
2022 Q1	–	Sell	-4,572	Closed	-$59K	–	2102
2021 Q4	$59K	Buy	+4,572	New	+$72.9K	0.01%	1299
2021 Q2	–	Sell	-3,720	Closed	-$81K	–	2141
2021 Q1	$81K	Buy	3,720 +1,760	+90%	+$46.3K	0.01%	1370
2020 Q4	$40K	Buy	+1,960	New	+$23.7K	﹤0.01%	1266
2019 Q4	–	Sell	-3,506	Closed	-$42K	–	1915
2019 Q3	$42K	Buy	+3,506	New	+$125K	﹤0.01%	1219
2018 Q4	–	Sell	-109	Closed	-$37K	–	2041
2018 Q3	$37K	Buy	+109	New	+$42.6K	﹤0.01%	1345

Other funds holding XBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Virtu Financial's XBIO Position: Q4 2022 in Review

Virtu Financial sold out of Xenetic Biosciences (XBIO) in Q4 2022, closing a stake of 1,973 shares — an estimated $11K sold.

Virtu Financial first reported a position in XBIO in Q3 2018 and held it in 6 quarters. The position peaked at $81K in Q1 2021. 19 funds tracked by Wall St. Rank hold XBIO as of Q4 2022.

Virtu Financial reported no remaining Xenetic Biosciences position as of Q4 2022 after selling out during the quarter.
Virtu Financial sold 1,973 Xenetic Biosciences shares in Q4 2022, an estimated $11K.
Virtu Financial first reported a position in Xenetic Biosciences in Q3 2018 and held it in 6 quarters.
Virtu Financial's Xenetic Biosciences position peaked at $81K in Q1 2021.
19 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q4 2022.

Based on Virtu Financial's 13F filing for Q4 2022, filed 15 Feb 2023.